Related Experiment Videos
Ranitidine multicenter study on slow-response duodenal ulcer patients
S Uleri1, G Visona, G Castelli
1Medical Department, Glaxo S.p.A., Verona, Italy.
Hepato-Gastroenterology
|February 1, 1994
Summary
Higher doses of ranitidine (300 mg twice daily) did not significantly improve duodenal ulcer healing rates compared to standard doses (150 mg twice daily) in slow-responding patients. Symptom relief was also similar between groups.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Duodenal ulcers are common gastrointestinal conditions.
- Identifying optimal ranitidine dosing for slow-responding patients is crucial for effective treatment.
Purpose of the Study:
- To compare the efficacy of ranitidine 150 mg twice daily versus 300 mg twice daily in healing duodenal ulcers in patients likely to be slow-responders.
- To assess symptom relief in these patient groups.
Main Methods:
- A double-blind study involving 26 Italian centers.
- Patients were selected based on clinical and anamnestic criteria for likely slow response.
- Treatment groups received either ranitidine 150 mg b.i.d. or 300 mg b.i.d.
Main Results:
- No statistically significant differences in healing rates were observed between the two ranitidine doses at 4 or 8 weeks.
- Four-week healing rates were 73.3% for 150 mg b.i.d. and 76.1% for 300 mg b.i.d.
- Cumulative 8-week healing rates were 91.5% and 93.9%, respectively, with no significant difference in symptom relief.
Conclusions:
- In this population of likely slow-responder duodenal ulcer patients, increasing ranitidine dosage did not offer a significant advantage in healing rates or symptom relief.
- Further research may be needed to identify other factors influencing response to ranitidine treatment.